MARCH 31, 2025 - RENEWAL DEADLINE
The BC Centre on Substance Use (BCCSU), in collaboration with the BC Ministry of Health, has released a new Guideline for the Clinical Management of Opioid Use Disorder. Effective June 5, 2017, this guideline is the provincial reference tool for all health care professionals in BC involved in treating patients with opioid use disorders.
To increase the transparency and awareness of the complaints process, the College has developed a suite of new resources.
A Fentanyl patch is a medication adhesive transdermal patch that is placed on the skin to deliver a specific dose of fentanyl through the skin. Improper disposal of these patches is a risk for diversion, illicit use and overdose. Accidental exposure to the patches can also cause serious harm to members of the public including children, pets, sanitation workers, as well as our water supply.
Did you know that the combination of clarithromycin and colchicine can cause serious adverse events such as rhabdomyolysis, pancytopenia and even death? Even though concomitant prescribing of the two drugs prompts the highest level of drug interaction severity, “major” or “severe”, in all major pharmacy software programs, patients are still being dispensed this combination.
PainBC’s integrated approach to pain management includes helping patients find the most effective medications to manage their chronic pain. Well-structured medication trials with collaboration between prescribers and pharmacists plays an important role in helping identify the most effective drug therapy for a patient.
Modern pharmacy practice in BC uses a number of pharmacy database systems such as PharmaNet for tasks including data collection and patient record management.
The College has received a number of inquiries about when our registrants are free from their responsibilities as pharmacy professionals. This seems like an odd question, but it’s come up more than once and in a number of different contexts...
A pilot study to reduce potential hospitalizations due to preventable drug-drug interactions
Earlier this year, the BCCSU and the Ministry of Health (MoH) released a new Guideline for the Clinical Management of Opioid Use Disorder. Starting on June 5, 2017, this guideline will become the provincial reference tool for all health care professionals in BC involved in treating patients with opioid use disorders, and the management of the Provincial Methadone Program will transition from the College of Physicians and Surgeons of British Columbia to the BCCSU.
Manufacturer Celopharma no longer requires pharmacists to undergo mandatory training prior to ordering and dispensing Mifegymiso.
In order to help registrants prepare for reviews, complete action items, and improve their practice, the College has introduced four new PRP support tools.
The PRP Support Tools provide comprehensive outlines of the requirements that comprise each of the four focus areas for pharmacy professionals in community practice.